Subscribe

Medications Used for the Treatment of Melanoma (Skin Cancer) and the Associated Codes

Cancer Drug Coding, Melanoma
Kristin A. Esposito, CPhT
Clinical Services Manager, RJ Health Systems

This detailed article of codes related to melanoma (skin cancer) is intended to assist practice managers and other healthcare providers and payers to ensure their proper use of coding and billing information associated with the treatment of patients with melanoma.

The following sections include:

  • Associated ICD-10-CM codes used for the classification of melanoma
  • Drugs that have been approved by the FDA for the treatment of melanoma
  • Drugs that are Compendia-listed for off-label use for melanoma based on clinical studies that suggest beneficial use in some cases. Please note: If a check mark appears in the FDA column, it will NOT appear in the Compendia off-label use column
  • Corresponding HCPCS/CPT® codes and code descriptions
  • Possible CPT® administration codes for the drugs

Associated ICD-10-CM Codes:

C43 Malignant melanoma of skin
  C43.0 Malignant melanoma of lip
  C43.1 Malignant melanoma of eyelid, including canthus
  C43.10 Malignant melanoma of unspecified eyelid, including canthus
  C43.11 Malignant melanoma of right eyelid, including canthus
  C43.12 Malignant melanoma of left eyelid, including canthus
  C43.2 Malignant melanoma of ear and external auricular canal
  C43.20 Malignant melanoma of unspecified ear and external auricular canal
  C43.21 Malignant melanoma of right ear and external auricular canal
  C43.22 Malignant melanoma of left ear and external auricular canal
  C43.3 Malignant melanoma of other and unspecified parts of face
  C43.30 Malignant melanoma of unspecified part of face
  C43.31 Malignant melanoma of nose
  C43.39 Malignant melanoma of other parts of face
  C43.4 Malignant melanoma of scalp and neck
  C43.5 Malignant melanoma of trunk
  C43.51 Malignant melanoma of anal skin
  C43.52 Malignant melanoma of skin of breast
  C43.59 Malignant melanoma of other part of trunk
  C43.6 Malignant melanoma of upper limb, including shoulder
  C43.60 Malignant melanoma of unspecified upper limb, including shoulder
  C43.61 Malignant melanoma of right upper limb, including shoulder
  C43.62 Malignant melanoma of left upper limb, including shoulder
  C43.7 Malignant melanoma of lower limb, including hip
  C43.70 Malignant melanoma of unspecified lower limb, including hip
  C43.71 Malignant melanoma of right lower limb, including hip
  C43.72 Malignant melanoma of left lower limb, including hip
  C43.8 Malignant melanoma of overlapping sites of skin
  C43.9 Malignant melanoma of skin, unspecified
Generic (brand) name HCPCS code—code description FDA approved for melanoma (skin cancer) Compendia off-label uses for melanoma (skin cancer) Possible CPT® administration codes
aldesleukin (Proleukin) J9015 - Injection, aldesleukin, per single-use vial ✔   96409
amifostine (Ethyol) J0207 - Injection, amifostine, 500 mg   ✔ 96374
Bacillus Calmette-Guerin (BCG Vaccine) 90585 - Bacillus Calmette-Guerin (BCG) vaccine for tuberculosis, live, for percutaneous use   ✔ 90471, 90472
Bacillus Calmette-Guerin vaccine (Tice BCG, TheraCys) 90586 - Bacillus Calmette-Guerin (BCG) vaccine for bladder cancer, live, for intravesical use   ✔ 51720
Bacillus Calmette-Guerin vaccine (Tice BCG, TheraCys) J9031 - BCG (intravesical), per installation   ✔ 51720
bleomycin (Blenoxane) J9040 - Injection, bleomycin sulfate, 15 units   ✔ 96401, 96409
carboplatin (Paraplatin) J9045 - Injection, carboplatin, 50 mg   ✔ 96409, 96413, 96415
carmustine (BiCNU) J9050 - Injection, carmustine, 100 mg   ✔ 96413, 96415
cisplatin (Platinol AQ) J9060 - Injection, cisplatin, powder or solution, per 10 mg   ✔ 96409, 96413, 96415
cobimetinib (Cotellic) C9399* - Unclassified drugs or biologicals (Hospital outpatient use only) ✔   N/A
cobimetinib (Cotellic) J8999* - Prescription drug, oral, chemotherapeutic, not otherwise specified ✔   N/A
dabrafenib (Tafinlar) C9399* - Unclassified drugs or biologicals (Hospital outpatient use only) ✔   N/A
dabrafenib (Tafinlar) J8999* - Prescription drug, oral, chemotherapeutic, not otherwise specified ✔   N/A
dacarbazine (DTIC-Dome) J9130 - Dacarbazine, 100 mg ✔   96409, 96413
dactinomycin (Cosmegen) J9120 - Injection, dactinomycin, 0.5 mg   ✔ 96409
docetaxel (Taxotere) J9171 - Injection, docetaxel, 1 mg   ✔ 96413
interferon alfa-2b (Intron-A) J9214 - Injection, interferon, alfa-2b, recombinant, 1 million units ✔   96372, 96401
ipilimumab (Yervoy) J9228 - Injection, ipilimumab, 1 mg ✔   96413, 96415
lomustine (CeeNU, Gleostine) J8999* - Prescription drug, oral, chemotherapeutic, not otherwise specified   ✔ N/A
lomustine (CeeNU, Gleostine) S0178 - Lomustine, oral, 10 mg   ✔ N/A
megestrol acetate (Megace) J8999* - Prescription drug, oral, chemotherapeutic, not otherwise specified   ✔ N/A
megestrol acetate (Megace) S0179 - Megestrol acetate, oral 20 mg   ✔ N/A
melphalan (Alkeran) J9245 - Injection, melphalan hydrochloride, 50 mg   ✔ 96409, 96413
nivolumab (Opdivo) J9299 - Injection, nivolumab, 1 mg ✔   96413, 96415
paclitaxel (Taxol) J9265 - Injection, paclitaxel, 30 mg   ✔ 96413, 96415
peginterferon alfa-2b (Sylatron) C9399* - Unclassified drugs or biologicals (Hospital outpatient use only) ✔   96372, 96401
peginterferon alfa-2b (Sylatron) J9999* - Not otherwise classified, antineoplastic drugs ✔   96372, 96401
pembrolizumab (Keytruda) J9271 - Injection, pembrolizumab, 1 mg ✔   96413
sargramostim (Leukine) J2820 - Injection, sargramostim (GM-CSF), 50 mcg   ✔ 96365, 96366, 96372
temozolomide (Temodar) J8700 - Temozolomide, oral, 5 mg   ✔ N/A
trametinib (Mekinist) C9399* - Unclassified drugs or biologicals (Hospital outpatient use only) ✔   N/A
trametinib (Mekinist) J8999* - Prescription drug, oral, chemotherapeutic, not otherwise specified ✔   N/A
vemurafenib (Zelboraf) C9399* - Unclassified drugs or biologicals (Hospital outpatient use only) ✔   N/A
vemurafenib (Zelboraf) J8999* - Prescription drug, oral, chemotherapeutic, not otherwise specified ✔   N/A
vinBLAStine (Velban) J9360 - Injection, vinblastine sulfate, 1 mg   ✔ 96409
vinCRIStine (Vincasar PFS) J9370 - Vincristine sulfate, 1 mg   ✔ 96409
*When billing a nonclassified medication using a CMS 1500 claim form you must include both the HCPCS code (eg, J8999 Zelboraf) in Item 24D and the drug name, strength, and NDC (National Drug Code) in Item 19 or 24A (shaded area) to ensure appropriate reimbursement. Please note: Check with your payer regarding the correct placement of medication information.
References
• HCPCS Level II Expert 2016
• Current Procedural Terminology (CPT®) 2016
• CPT Copyright © 2016 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association
• ICD-10-CM for Professionals Volumes 1 & 2 2016
• FDA-approved indication (product Prescribing Information)
• Compendia references available upon request
• www.ReimbursementCodes.com powered by RJ Health Systems International, LLC, Rocky Hill, CT
• CMS (Centers for Medicare & Medicaid Services)
GM-CSF indicates granulocyte-macrophage colony-stimulating factor; HCPCS, Healthcare Common Procedure Coding System.
This information was supplied by
30 Cold Spring Road, Rocky Hill, CT 06067 • T: (860) 563-1223 F: (860) 563-1650

Related Articles

Personalized Neoadjuvant Immunotherapy Combinations Improve Outcomes in Stage III Melanoma
By Wayne Kuznar
June 2019, Vol 9, No 6
Melanoma
FDA Approves Second Indication for Keytruda in the Treatment of Melanoma
March 2019, Vol 9, No 3
FDA Approvals, News & Updates, Melanoma
FDA Approves Pembrolizumab for Treatment of Advanced Melanoma
Web Exclusives
FDA Approvals, News & Updates, Melanoma
Medications Used for the Treatment of Bladder Cancer and Associated ICD-10 Coding
By Kristin A. Esposito, CPhT
December 2017, Vol 7, No 12
Cancer Drug Coding, ICD Codes, Reimbursement
CONNECT
Subscribe

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve:

Sign Up for Oncology News

Subscribe to recieve the free, monthly OPM print publication and OPM weekly e‑newsletter.

Subscribe
© 2020 Engage Healthcare Communications, LLC. All Rights Reserved. Privacy Policy.